Vertex Pharmaceuticals

SPublicFounded 1989🇺🇸Boston, Massachusetts

CEO

Reshma Kewalramani

Data verified as of Jul 8, 2026

Summary

Vertex Pharmaceuticals is the world leader in cystic fibrosis (CF) and one of biotech's few large-cap, highly profitable, self-funded innovators. Its CFTR-modulator franchise — anchored by Trikafta/Kaftrio and the next-generation once-daily Alyftrek (vanzacaftor/tezacaftor/deutivacaftor, FDA-approved December 2024) — treats the large majority of the addressable CF population and generated the bulk of $12.0B in FY2025 revenue, with $4.0B of GAAP net income. Vertex is now deploying that cash flow to diversify well beyond CF. It commercialized Casgevy (exagamglogene autotemcel), the first CRISPR/Cas9 gene-editing therapy ever approved, for sickle cell disease and beta thalassemia, partnered with CRISPR Therapeutics. In January 2025 it launched Journavx (suzetrigine), the first genuinely new class of pain medicine in over two decades — an oral, non-opioid NaV1.8 inhibitor. Its pipeline includes zimislecel (VX-880), a stem-cell-derived islet therapy that has rendered type 1 diabetes patients insulin-independent in trials; inaxaplin for APOL1-mediated kidney disease; and povetacicept (from the $4.9B Alpine acquisition) for IgA nephropathy. In July 2026 it agreed to acquire endocrine-disease specialist Crinetics Pharmaceuticals for ~$10B — its largest-ever acquisition — adding the marketed acromegaly drug Palsonify and an endocrinology pipeline. Vertex pushes the envelope by turning single-gene biology into functional cures.

Main Products

Trikafta / Kaftrio

Active

Vertex's flagship cystic fibrosis triple-combination CFTR modulator (elexacaftor/tezacaftor/ivacaftor), effective for roughly 90% of CF patients and the company's dominant revenue engine — now complemented by the once-daily next-generation Alyftrek.

The CF standard of care worldwide. Vertex is converting patients onto the once-daily Alyftrek (approved December 2024) and expanding ex-US launches and younger-age labels to sustain franchise growth.

US CF Revenue (2025)$7.55B (+13% YoY)

Patient Coverage~90% of CF patients (Trikafta)

Journavx (suzetrigine)

Active

A first-in-class oral, non-opioid pain medicine (VX-548) that selectively inhibits the NaV1.8 sodium channel to block pain signals in the peripheral nervous system before they reach the brain — the first new class of pain drug in over 20 years.

FDA-approved January 30, 2025 for moderate-to-severe acute pain and launching commercially, with label-expansion studies into chronic pain (including diabetic peripheral neuropathy) under way.

FDA ApprovalJan 2025 (acute pain)

MechanismSelective NaV1.8 inhibitor (non-opioid)

Casgevy (exa-cel)

Active

The first approved CRISPR/Cas9 gene-editing medicine (exagamglogene autotemcel), a one-time therapy for sickle cell disease and transfusion-dependent beta thalassemia, developed and commercialized with CRISPR Therapeutics.

Approved across multiple jurisdictions and priced at ~$2.2M per one-time treatment. Vertex books the revenue (~$116M in FY2025) and is scaling a global network of authorized treatment centers; in July 2026 the US label expanded to patients ages 2+.

First ApprovalNov 2023 (UK); Dec 2023 (US)

Patients Started>500 cumulative (Q1 2026)

Zimislecel (VX-880)

In Development

An allogeneic, stem-cell-derived, fully differentiated islet cell therapy for type 1 diabetes designed to restore the body's own insulin production — a potential functional cure delivered as a one-time infusion.

In a pivotal Phase 1/2/3 program with FDA RMAT and Fast Track, EMA PRIME, and a UK Innovation Passport. All 10 participants in the reported cohort became insulin-independent at one year with >90% time-in-range; global regulatory submissions are expected in 2026.

Phase 1/2 Result10/10 insulin-independent at 1 year

ModalityStem-cell-derived islet cell therapy

What's Next

Close the ~$10B Crinetics acquisition

Complete the agreed ~$10B cash acquisition of Crinetics Pharmaceuticals (expected Q3 2026) and integrate its marketed acromegaly drug Palsonify and endocrinology pipeline — Vertex's largest-ever deal and its entry into endocrine disease.

Q3 2026

Zimislecel type 1 diabetes regulatory submission

File global regulatory submissions for the stem-cell islet therapy that has produced insulin-independence — potential functional cures — in trial participants, a landmark for cell therapy.

2026

Povetacicept FDA decision in IgA nephropathy

Await the FDA decision on povetacicept (from the Alpine acquisition) for IgA nephropathy after Phase 3 RAINIER showed a 52% reduction in proteinuria; a PDUFA target date is set for late 2026.

Nov 2026

Inaxaplin APOL1 kidney disease Phase 3

Advance the AMPLITUDE Phase 3 trial of inaxaplin (VX-147), a once-daily oral therapy that could be the first treatment targeting the underlying cause of APOL1-mediated kidney disease.

2026+

Journavx label expansion into chronic pain

Broaden Journavx beyond acute pain into chronic indications such as diabetic peripheral neuropathy, scaling the non-opioid franchise into a much larger market.

2026+

Alyftrek CF conversion and ex-US rollout

Convert Trikafta patients onto the once-daily Alyftrek and expand international launches to extend the cystic fibrosis franchise and drive continued CF revenue growth.

2026 ongoing

Recent News

View all →

Jul 8

Vertex to buy Crinetics for ~$10B in largest-ever deal

Vertex Pharmaceuticals agreed on July 6 to acquire endocrine-disease specialist Crinetics Pharmaceuticals for $85 per share in cash, valuing the San Diego company at roughly $10 billion — Vertex's largest acquisition to date and about a 102% premium to Crinetics' prior close. The deal hands Vertex Palsonify (paltusotine), an oral once-daily drug approved in September 2025 for acromegaly, plus an endocrinology pipeline the companies say could deliver more than $5 billion in combined peak annual revenue. Approved by both boards, the transaction is expected to close in the third quarter of 2026 and become accretive to non-GAAP operating income in 2029.

Jul 5

FDA expands Casgevy gene therapy to children as young as 2

The U.S. FDA on July 1 approved expanded use of Casgevy (exagamglogene autotemcel) — the world's first approved CRISPR/Cas9 gene-editing medicine, developed by Vertex Pharmaceuticals with CRISPR Therapeutics — for patients ages 2 and older with sickle cell disease or transfusion-dependent beta thalassemia, lowering the prior age floor of 12. Vertex said the expansion makes roughly 5,500 additional U.S. children newly eligible for the one-time therapy. CRISPR shares rose about 8% and Vertex about 6% on the news; CRISPR retains roughly 40% of Casgevy's economics under the partnership.

CRISPR Therapeutics

Operations & Revenue

StatusProfitable, commercial-scale

Vertex runs a dominant, high-margin cystic fibrosis franchise (US CF revenue rose 13% to $7.55B in 2025) that funds an aggressive diversification into non-opioid pain, CRISPR gene therapy, type 1 diabetes cell therapy, and kidney disease. FY2025 GAAP net income of $4.0B and ~$12.3B in cash give it ample firepower for internal R&D, M&A, and a $2.0B annual buyback — a rare profitable, self-funded innovator at biotech's frontier.

Revenue Streams

Cystic fibrosis franchise

The overwhelming majority of revenue: Trikafta/Kaftrio plus the next-generation once-daily Alyftrek. US CF revenue grew 13% to $7.55B in 2025, with further growth from ex-US Alyftrek launches and label expansions to younger patients.

Journavx (acute pain)

Vertex's newly launched non-opioid pain medicine, generating early commercial revenue as it builds formulary access; more than 1 million prescriptions had been written by early 2026.

Casgevy (gene therapy)

The CRISPR gene-editing therapy for sickle cell disease and beta thalassemia, co-commercialized with CRISPR Therapeutics; Vertex books the product revenue (~$116M in FY2025) as authorized treatment centers scale globally.

Emerging (diabetes & kidney disease)

Future streams from zimislecel (type 1 diabetes), inaxaplin (APOL1-mediated kidney disease), and povetacicept (IgA nephropathy) as these programs approach the market.

Key Metrics

Employees

~6,400

Est. Annual Revenue

$12.0B (FY2025); 2026 guidance of $12.95–13.1B including $500M+ from non-CF products

FY2025 Revenue

$12.0B (+9% YoY)

FY2025 GAAP Net Income

$4.0B (rebound from 2024 IPR&D-driven loss)

Cash & Investments

~$12.3B (Dec 31, 2025)

Market Cap

~$130B+

FY2025 R&D Spend

$3.9B (GAAP)

Journavx Uptake

>1M prescriptions written since Jan 2025 launch

Approved Products

5 CF modulators + Journavx (pain) + Casgevy (gene therapy)

Timeline

2026Record year: $12.0B revenue, $4.0B net income

Reports FY2025 revenue of $12.0B (+9%) and GAAP net income of $4.0B, guiding to $12.95–13.1B for 2026 including $500M+ from non-CF products, and continuing a $2.0B annual share-buyback program.

2026Agrees to acquire Crinetics for ~$10B — largest deal ever

On July 6, 2026 Vertex agrees to acquire endocrine-disease specialist Crinetics Pharmaceuticals for $85 per share in cash (~$10B, about a 102% premium) — its largest acquisition to date. The deal adds Palsonify (paltusotine), an oral once-daily acromegaly drug approved in September 2025, plus an endocrinology pipeline the companies say could deliver $5B+ in combined peak annual revenue. Closing is expected in Q3 2026.

2025Journavx (suzetrigine) — first new pain-drug class in 20+ years

On January 30, 2025 the FDA approves Journavx (suzetrigine), a first-in-class oral, non-opioid NaV1.8 inhibitor for moderate-to-severe acute pain — the first genuinely new class of pain medicine in more than two decades.

2025Zimislecel delivers functional cures in type 1 diabetes

At the June 2025 ADA meeting, Vertex reports that all 10 type 1 diabetes participants dosed with zimislecel became insulin-independent at one year with >90% time-in-range; the data are published in the New England Journal of Medicine.

2024Alpine Immune Sciences acquisition ($4.9B)

Acquires Alpine Immune Sciences for ~$4.9B, adding povetacicept (a BAFF/APRIL inhibitor) and a broader immunology and nephrology pipeline. The one-time acquired-IPR&D charge drove a temporary GAAP net loss that year.

2024Alyftrek — next-generation once-daily CF combo approved

The FDA approves Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) in December 2024, a once-daily next-in-class CFTR modulator that Vertex begins converting patients onto to extend its CF franchise.

2023Casgevy becomes the world's first approved CRISPR medicine

Casgevy (exa-cel), developed with CRISPR Therapeutics, is authorized by the UK MHRA in November 2023 and approved by the FDA for sickle cell disease in December 2023 — the first CRISPR/Cas9 gene-editing therapy ever approved.

2019Trikafta approved — the transformational triple combo

The FDA approves Trikafta (elexacaftor/tezacaftor/ivacaftor), a triple-combination modulator that is effective for roughly 90% of CF patients and becomes Vertex's revenue engine.

2019Acquires Semma Therapeutics for diabetes cell therapy

Buys Semma Therapeutics for ~$950M, entering stem-cell-derived islet therapy for type 1 diabetes — the program that became zimislecel (VX-880).

2015Orkambi and the CRISPR Therapeutics partnership

Launches Orkambi, its first CFTR combination therapy, and forms a gene-editing partnership with CRISPR Therapeutics that would later produce Casgevy.

2012Kalydeco — first drug to treat CF's underlying cause

The FDA approves Kalydeco (ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis rather than just its symptoms, and the first CFTR potentiator.

1991IPO on NASDAQ (VRTX)

Goes public on NASDAQ under ticker VRTX, funding an early pipeline that spanned HIV and hepatitis C before its pivot to cystic fibrosis.

1989Founded to industrialize structure-based drug design

Joshua Boger and Kevin Kinsella found Vertex in Cambridge, Massachusetts, to transform the treatment of serious diseases through rational, structure-based drug design.

Funding

Cumulative disclosed raise · dated rounds

Round	Date	Amount	Investors
IPO (NASDAQ: VRTX)	1991	Public since 1991	Public markets; now a Nasdaq-100 and S&P 500 component
Semma Therapeutics acquisition	2019	~$950M	Capital deployment (type 1 diabetes cell therapy)
ViaCyte acquisition	2022	~$320M	Capital deployment (diabetes cell-therapy assets)
Alpine Immune Sciences acquisition	2024	~$4.9B	Capital deployment (povetacicept; immunology/nephrology)
Crinetics Pharmaceuticals acquisition (agreed)	2026	~$10B ($85/share cash)	Capital deployment (Palsonify; endocrinology). Expected to close Q3 2026
Share repurchases	2025	$2.0B (annual buyback)	Self-funded from operating cash flow